27 Mar 2026Open access
Uterine leiomyoma mimicking a gastrointestinal stromal tumor: a diagnostic pitfall of CD117 positivity – case report and review of the literaturePublisher siteBMC Women s Health, Uterine Myomas and Treatments
Active, last published 2026
In gastrointestinal tumor research and treatment
Rime
Amari
Scholar“Research focused on Gastrointestinal Tumor Research and Treatment and adjacent fields.”
University of Tunis El Manar
Tunisia
Claim Your ProfileTunisia0
H-index
0
Citations
Rime has not officially claimed their profile. If you are Rime, claim it free.
Claim Your Profile
Pioneer
LOCKED
Pathfinder
LOCKED
Scholar
EARNED
Innovator
LOCKED
Inventor
LOCKED
Catalyst
LOCKED
Expert
UPGRADE
01 · About the work
What I study
ime Amari is a researcher working on Gastrointestinal Tumor Research and Treatment. A fuller summary will appear once they update their profile.
02 · Reach
Publication output and reach
Rime's work has been cited 0 times across 1 active year. Bars show publications per year; the line shows cumulative citation totals across publications first appearing in each year.
03 · Research focus
Topics
Gastrointestinal Tumor Research and Treatment×2
04 · Where I am
Affiliations
Affiliation on published researchTunis El Manar University, TunisiaDrawn from the institution listed on this researcher’s published work.
Research themes (UN SDGs)
05 · Selected work
Recent publications
2 works17 Mar 2026Open access
Preoperative prediction of complicated acute appendicitis using the appendicitis inflammatory response (AIR) scorePublisher siteCurrent Problems in Surgery, Appendicitis Diagnosis and Management
Expert Academic Profiles go further
Citation trend analytics, exportable publication records, and direct enquiry routing from industry and funders.
Are you Rime?
Claim it to verify your details, connect with industry partners, and explore Fractional Domain Expert opportunities through MARATTO™.
African researchers are full of potential that too often goes unrecognised. Your MARATTO™ profile gives your work the commercial pathway it deserves.
Claim Your Profile
Free to claim · takes a minute to verify it’s you